Literature DB >> 23651020

Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics.

Julie A Johnson1, Amanda R Elsey, Michael J Clare-Salzler, David Nessl, Michael Conlon, David R Nelson.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23651020      PMCID： PMC3684075          DOI： 10.2217/pgs.13.59

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


× No keyword cloud information.
  5 in total

1.  Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.

Authors:  M V Relling; E E Gardner; W J Sandborn; K Schmiegelow; C-H Pui; S W Yee; C M Stein; M Carrillo; W E Evans; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

2.  Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.

Authors:  K R Crews; A Gaedigk; H M Dunnenberger; T E Klein; D D Shen; J T Callaghan; E D Kharasch; T C Skaar
Journal:  Clin Pharmacol Ther       Date:  2011-12-28       Impact factor: 6.875

Review 3.  Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.

Authors:  S A Scott; K Sangkuhl; E E Gardner; C M Stein; J-S Hulot; J A Johnson; D M Roden; T E Klein; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2011-06-29       Impact factor: 6.875

Review 4.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.

Authors:  J A Johnson; L Gong; M Whirl-Carrillo; B F Gage; S A Scott; C M Stein; J L Anderson; S E Kimmel; M T M Lee; M Pirmohamed; M Wadelius; T E Klein; R B Altman
Journal:  Clin Pharmacol Ther       Date:  2011-09-07       Impact factor: 6.875

Review 5.  Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array.

Authors:  J A Johnson; B M Burkley; T Y Langaee; M J Clare-Salzler; T E Klein; R B Altman
Journal:  Clin Pharmacol Ther       Date:  2012-08-22       Impact factor: 6.875
  5 in total
  44 in total

Review 1.  The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.

Authors:  Yao Yang; Joshua P Lewis; Jean-Sébastien Hulot; Stuart A Scott
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-07-14       Impact factor: 4.481

2.  Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre-emptive pharmacogenomic testing.

Authors:  James E Kimpton; Iain M Carey; Christopher J D Threapleton; Alexandra Robinson; Tess Harris; Derek G Cook; Stephen DeWilde; Emma H Baker
Journal:  Br J Clin Pharmacol       Date:  2019-12-13       Impact factor: 4.335

3.  A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care.

Authors:  Paul C D Bank; Jesse J Swen; Rowena D Schaap; Daniëlle B Klootwijk; Renée Baak-Pablo; Henk-Jan Guchelaar
Journal:  Eur J Hum Genet       Date:  2019-06-21       Impact factor: 4.246

Review 4.  Surveying Recent Themes in Translational Bioinformatics: Big Data in EHRs, Omics for Drugs, and Personal Genomics.

Authors:  J C Denny
Journal:  Yearb Med Inform       Date:  2014-08-15

Review 5.  Institutional profile: University of Florida Health Personalized Medicine Program.

Authors:  Larisa H Cavallari; Kristin W Weitzel; Amanda R Elsey; Xinyue Liu; Scott A Mosley; Donald M Smith; Benjamin J Staley; Almut G Winterstein; Carol A Mathews; Francesco Franchi; Fabiana Rollini; Dominick J Angiolillo; Petr Starostik; Michael J Clare-Salzler; David R Nelson; Julie A Johnson
Journal:  Pharmacogenomics       Date:  2017-03-27       Impact factor: 2.533

6.  A brighter future for the implementation of pharmacogenomic testing.

Authors:  Cathelijne H van der Wouden; Jesse J Swen; Matthias Samwald; Christina Mitropoulou; Matthias Schwab; Henk-Jan Guchelaar
Journal:  Eur J Hum Genet       Date:  2016-08-31       Impact factor: 4.246

Review 7.  Systems biology approaches to adverse drug effects: the example of cardio-oncology.

Authors:  Sherry-Ann Brown; Nicole Sandhu; Joerg Herrmann
Journal:  Nat Rev Clin Oncol       Date:  2015-10-13       Impact factor: 66.675

8.  Iterative Development and Evaluation of a Pharmacogenomic-Guided Clinical Decision Support System for Warfarin Dosing.

Authors:  Brittany L Melton; Alan J Zillich; Jason Saleem; Alissa L Russ; James E Tisdale; Brian R Overholser
Journal:  Appl Clin Inform       Date:  2016-11-23       Impact factor: 2.342

9.  Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program.

Authors:  Alan R Shuldiner; Kathleen Palmer; Ruth E Pakyz; Tameka D Alestock; Kristin A Maloney; Courtney O'Neill; Shaun Bhatty; Jamie Schub; Casey Lynnette Overby; Richard B Horenstein; Toni I Pollin; Mark D Kelemen; Amber L Beitelshees; Shawn W Robinson; Miriam G Blitzer; Patrick F McArdle; Lawrence Brown; Linda Jo Bone Jeng; Richard Y Zhao; Nicholas Ambulos; Mark R Vesely
Journal:  Am J Med Genet C Semin Med Genet       Date:  2014-03-10       Impact factor: 3.908

10.  Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association.

Authors:  Jennifer L Hall; John J Ryan; Bruce E Bray; Candice Brown; David Lanfear; L Kristin Newby; Mary V Relling; Neil J Risch; Dan M Roden; Stanley Y Shaw; James E Tcheng; Jessica Tenenbaum; Thomas N Wang; William S Weintraub
Journal:  Circ Cardiovasc Genet       Date:  2016-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.